Please login to the form below

Not currently logged in
Email:
Password:

UK pledges £220m tech fund for life science and university sectors

ABPI says investment will be well received by the pharma industry
ABPI

The UK government is set to invest £220m in a package of measures for the life science and university sectors to support the use of cutting edge technologies.

The support was announced by the chancellor Philip Hammond over the weekend and half of it will be tailored to help translate medical technology breakthroughs into commercial success.

The investment was welcomed by industry body the ABPI, which said it "demonstrates the Government's continued support for the UK life sciences industry".

Chief executive Mike Thompson hailed the four-year funding plan as a “clear signal from Government that the UK remains a great place for life sciences and will be well received by all in the industry”.

Nearly half of the funding - £100m - has been earmarked for the Biomedical Catalyst (BMC), an accelerative novel products programme created by the government-funded bodies Medical Research Council and Innovate UK.

This will see grants awarded for the development of disruptive healthcare technologies in disease prevention, earlier diagnosis and personalised medicines from feasibility studies through to early clinical trials.

The remaining £120m will be used to incentivise academic collaborations with pharma and other sectors, sharing technologies to help transform university-led research into viable business ventures, like Nottingham University's cancer detection project Oncimmune which is developing a blood test for lung cancer.

Commenting on the announcement, which came on the eve of the Conservative Party conference in Birmingham, Thompson said: “We hope that today's investment is just a first step.

“We look forward to the publication of the Accelorated Access Review in the coming weeks which should drive further investment and innovation in our sector and help improve access to innovative medicines and treatments for NHS patients.”

Article by
Rebecca Clifford

3rd October 2016

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics